Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP Operations | February 03, 2004 | February 04, 2004 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 03, 2004 · Filed February 04, 2004
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 203,772 |
Reported balance
After 2004-02-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2004-02-03 · Exercise / conversion · Acquired 9,716 · Balance 203,772 |
| Common StockSEC Table I · non-derivative | Direct | 243,772 |
Reported balance
After 2004-02-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2004-02-03 · Exercise / conversion · Acquired 40,000 · Balance 243,772 |
| Common StockSEC Table I · non-derivative | Direct | 246,056 |
Reported balance
After 2004-02-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2004-02-03 · Exercise / conversion · Acquired 2,284 · Balance 246,056 |
| Common StockSEC Table I · non-derivative | Direct | 238,556 |
Reported balance
After 2004-02-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2004-02-03 · Sale · Disposed 7,500 · Balance 238,556 |
| Common StockSEC Table I · non-derivative | Direct | 226,056 |
Reported balance
After 2004-02-03 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2004-02-03 · Sale · Disposed 12,500 · Balance 226,056 |
| Common StockSEC Table I · non-derivative | Direct | 211,056 |
Reported balance
After 2004-02-03 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2004-02-03 · Sale · Disposed 15,000 · Balance 211,056 |
| Common StockSEC Table I · non-derivative | Direct | 206,056 |
Reported balance
After 2004-02-03 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2004-02-03 · Sale · Disposed 5,000 · Balance 206,056 |
| Common StockSEC Table I · non-derivative | Direct | 201,056 |
Reported balance
After 2004-02-03 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2004-02-03 · Sale · Disposed 5,000 · Balance 201,056 |
| Common StockSEC Table I · non-derivative | Direct | 196,340 |
Reported balance
After 2004-02-03 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2004-02-03 · Sale · Disposed 4,716 · Balance 196,340 |
| Common StockSEC Table I · non-derivative | Direct | 196,040 |
Reported balance
After 2004-02-03 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2004-02-03 · Gift · Disposed 300 · Balance 196,040 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. |
| Common StockSEC Table I · non-derivative | Indirectby Son | 5,600 |
Reported balance
After 2004-02-03 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2004-02-03 · Gift · Acquired 300 · Balance 5,600 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22 | Direct | 4,568 |
Reported balance
After 2004-02-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2004-02-03 · Exercise / conversion · Disposed 2,284 · Balance 4,568 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22 | Direct | 19,432 |
Reported balance
After 2004-02-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2004-02-03 · Exercise / conversion · Disposed 9,716 · Balance 19,432 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2010-04-05 | Direct | 53,252 |
Reported balance
After 2004-02-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2004-02-03 · Exercise / conversion · Disposed 40,000 · Balance 53,252 F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents transfer of shares to son under Uniform Gift to Minors Act.
F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.
F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005.
F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 37,865 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
MyoKardia, Inc.
Report date November 17, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 1
1 source rowRow 1 · 2020-11-17 · Other · Disposed 29,508 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-17 · Disposition to issuer · Disposed 21,800 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
NVIDIA CORP
Report date June 26, 2024 · Filed June 26, 2024
Section 16 reporting ended · disclosed 2024-06-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2003 Filed Nov 4, 2003 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $54.64 | $273,200.00 |
DisclosureSEC source: 0001179110-03-009848 · edgar.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,039 Read SEC document |
| October 31, 2003 Filed Nov 4, 2003 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $54.55 | $272,750.00 |
DisclosureSEC source: 0001179110-03-009848 · edgar.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,039 Read SEC document |
| October 31, 2003 Filed Nov 4, 2003 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,000 | $54.28 | $1,085,500.00 |
DisclosureSEC source: 0001179110-03-009848 · edgar.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,039 Read SEC document |
| October 31, 2003 Filed Nov 4, 2003 01:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 44,000 | $14.59 | $642,127.20 |
DisclosureSEC source: 0001179110-03-009848 · edgar.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · derivative · entry 17 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,148 Underlying: Common Stock · 10,000 shares Expires 2009-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $62.11 | $310,550.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 13 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,039 F1 · balance_after: All shares and dollar amounts reflect two-for-one stock splits in February 2001 and March 2002. F2 · balance_after: Amount of securities beneficially owned (Table I, Col. 5) includes 699 shares acquired under the Gilead Sciences. Inc. Employee Stock Purchase Plan on 6/30/03. Read SEC document |
| August 06, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $61.17 | $152,925.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 12 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,039 Read SEC document |
| August 06, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $62.00 | $155,000.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 11 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,539 Read SEC document |
| August 06, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $14.59 | $145,938.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 10 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 40,000 | $0.00 Strike: $14.59 | $0.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · derivative · entry 16 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,148 Underlying: Common Stock · 40,000 shares Expires 2009-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,344 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · derivative · entry 15 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,344 shares Expires 2008-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,656 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · derivative · entry 14 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,656 shares Expires 2008-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $65.39 | $326,950.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 9 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,039 Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,000 | $65.22 | $521,760.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 8 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,039 Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $65.20 | $326,000.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 7 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,039 Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $65.10 | $325,500.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 6 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,039 Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $65.05 | $325,250.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 5 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,039 Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,344 | $65.00 | $932,360.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,039 Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 40,000 | $14.59 | $583,752.00 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,344 | $5.72 | $13,404.87 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2003 Filed Aug 7, 2003 21:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,656 | $5.72 | $66,658.33 |
DisclosureSEC source: 0001179110-03-005134 · edgar.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · EVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.